FLT
Los inhibidores de la FLT (quinasa de tirosina similar a Fms) son compuestos que se dirigen a los receptores FLT, los cuales están involucrados en la regulación de la angiogénesis a través de la vía del VEGF (factor de crecimiento endotelial vascular). Los receptores FLT desempeñan un papel crucial en el desarrollo de nuevos vasos sanguíneos en los tumores. Inhibir los receptores FLT puede reducir eficazmente la angiogénesis y el crecimiento tumoral, lo que hace que estos inhibidores sean importantes en la terapia contra el cáncer. En CymitQuimica, ofrecemos una selección de inhibidores de FLT de alta calidad para apoyar su investigación en oncología, biología vascular y angiogénesis.
Se han encontrado 88 productos de "FLT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRX-2843
CAS:MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).Fórmula:C29H40N6OPureza:98.59% - 99.63%Forma y color:SolidPeso molecular:488.67Ref: TM-T16144
1mg62,00€5mg138,00€10mg215,00€25mg430,00€50mg622,00€100mg887,00€1mL*10mM (DMSO)148,00€FLT3-IN-3
CAS:FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.Fórmula:C27H38N8OPureza:99.25%Forma y color:SolidPeso molecular:490.64Ref: TM-T11298
1mg107,00€5mg259,00€10mg432,00€25mg715,00€50mg1.008,00€100mg1.359,00€500mg2.717,00€1mL*10mM (DMSO)278,00€FLT3/HDAC-IN-2
Compound 25h, also known as FLT3/HDAC-IN-2, is a dual inhibitor of FLT3/HDAC. It exhibits antiproliferative activity against MOLM-13 cells and is used in the study of acute myeloid leukemia.Forma y color:Odour SolidPROTAC FLT-3 degrader 3
PROTACFLT-3degrader 3 (compound 35) is a PROTAC degrader of FLT. It exhibits antiproliferative activity, with an IC50 value of 7.55 nM in MV4-11 cells.Fórmula:C48H44Cl2N10O6Peso molecular:926.28223FLT3 Ligand-Linker Conjugate 1
CAS:FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Fórmula:C29H34N6O4S2Forma y color:SolidPeso molecular:594.7482-Butenamide
CAS:2-Butenamide, FLT3 inhibitor. Affordable Excellence: Reliable Quality You Can TrustFórmula:C4H7NOForma y color:SolidPeso molecular:85.1FLT3-IN-24
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase, with an IC50 of 7.94 nM. It also exhibits anti-proliferative effects on cells.Fórmula:C23H20N6O2SPeso molecular:444.13685FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Fórmula:C29H35N7O5Forma y color:SolidPeso molecular:561.63FLT3-IN-20
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.Fórmula:C28H33N7O2SForma y color:SolidPeso molecular:531.67FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Fórmula:C24H22N6O2Forma y color:SolidPeso molecular:426.47FLT3-ITD-IN-2
FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.Fórmula:C39H50N8O6Forma y color:SolidPeso molecular:726.86FLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsForma y color:Odour SolidPacritinib citrate
CAS:Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM). It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM). This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].Fórmula:C34H40N4O10Forma y color:SolidPeso molecular:664.7JAK3-IN-14
CAS:JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Fórmula:C18H13N3OPureza:98.29%Forma y color:SoildPeso molecular:287.32Ref: TM-T67754
1mg167,00€5mg409,00€10mg595,00€25mg888,00€50mg1.234,00€100mg1.665,00€1mL*10mM (DMSO)358,00€3-Hydroxy Midostaurin
CAS:3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM inFórmula:C35H30N4O5Pureza:98%Forma y color:SolidPeso molecular:586.648HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Forma y color:Odour SolidPF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Fórmula:C46H50F3N13O8Pureza:98%Forma y color:SolidPeso molecular:969.97PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Fórmula:C44H49N13O6Pureza:98%Forma y color:SolidPeso molecular:855.94PROTAC FLT3/GSPT1/IKZF1/3 degrader-1
PROTACFLT3/GSPT1/IKZF1/3 degrader-1 is an FLT3 PROTAC degrader with DC50 = 1.2 nM. It functions as a molecular glue to degrade its brain substrates and exhibits antiproliferative activity against resistant acute myeloid leukemia (AML) cells, showing potential applications in AML research.Forma y color:Odour SolidEmirodatamab
CAS:Emirodatamab (AMG-427) is an anti-FLT3/CD3 bispecific T-cell engager with an extended half-life. It can induce high cytotoxicity in primary AML progenitor cells and enhance FLT-3 expression. Combining Emirodatamab with anti-PD-1 antibodies increases T-cell dependent cytotoxicity (TDCC). This compound is under investigation for use in relapsed or refractory AML.
